175 related articles for article (PubMed ID: 35588154)
1. P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.
Wanhainen KM; Peng C; Zhou MH; Macedo BG; O'Flanagan S; Yang T; Kelekar A; Burbach BJ; Borges da Silva H; Jameson SC
Cancer Immunol Res; 2022 Jul; 10(7):871-884. PubMed ID: 35588154
[TBL] [Abstract][Full Text] [Related]
2. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8
Borges da Silva H; Beura LK; Wang H; Hanse EA; Gore R; Scott MC; Walsh DA; Block KE; Fonseca R; Yan Y; Hippen KL; Blazar BR; Masopust D; Kelekar A; Vulchanova L; Hogquist KA; Jameson SC
Nature; 2018 Jul; 559(7713):264-268. PubMed ID: 29973721
[TBL] [Abstract][Full Text] [Related]
3. Sensing of ATP via the Purinergic Receptor P2RX7 Promotes CD8
Borges da Silva H; Peng C; Wang H; Wanhainen KM; Ma C; Lopez S; Khoruts A; Zhang N; Jameson SC
Immunity; 2020 Jul; 53(1):158-171.e6. PubMed ID: 32640257
[TBL] [Abstract][Full Text] [Related]
4. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
[TBL] [Abstract][Full Text] [Related]
5. The Extracellular ATP Receptor P2RX7 Imprints a Promemory Transcriptional Signature in Effector CD8
Vardam-Kaur T; van Dijk S; Peng C; Wanhainen KM; Jameson SC; Borges da Silva H
J Immunol; 2022 Apr; 208(7):1686-1699. PubMed ID: 35264459
[TBL] [Abstract][Full Text] [Related]
6. ARTC2.2/P2RX7 Signaling during Cell Isolation Distorts Function and Quantification of Tissue-Resident CD8
Borges da Silva H; Wang H; Qian LJ; Hogquist KA; Jameson SC
J Immunol; 2019 Apr; 202(7):2153-2163. PubMed ID: 30777922
[TBL] [Abstract][Full Text] [Related]
7. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
8. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.
Young CN; Sinadinos A; Lefebvre A; Chan P; Arkle S; Vaudry D; Gorecki DC
Autophagy; 2015; 11(1):113-30. PubMed ID: 25700737
[TBL] [Abstract][Full Text] [Related]
9. Human P2Y
Dreisig K; Sund L; Dommer MW; Kristensen NP; Boddum K; Viste R; Fredholm S; Odum N; Jäättelä M; Skov S; Kornum BR
Front Immunol; 2018; 9():1159. PubMed ID: 29937766
[TBL] [Abstract][Full Text] [Related]
10. CD8
Mellouk A; Bobé P
FASEB J; 2019 Mar; 33(3):3225-3236. PubMed ID: 30383448
[TBL] [Abstract][Full Text] [Related]
11.
Stark R; Wesselink TH; Behr FM; Kragten NAM; Arens R; Koch-Nolte F; van Gisbergen KPJM; van Lier RAW
Sci Immunol; 2018 Dec; 3(30):. PubMed ID: 30552101
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
[TBL] [Abstract][Full Text] [Related]
13. Islet-Derived eATP Fuels Autoreactive CD8
Tezza S; Ben Nasr M; D'Addio F; Vergani A; Usuelli V; Falzoni S; Bassi R; Dellepiane S; Fotino C; Rossi C; Maestroni A; Solini A; Corradi D; Giani E; Mameli C; Bertuzzi F; Pezzolesi MG; Wasserfall CH; Atkinson MA; Füchtbauer EM; Ricordi C; Folli F; Di Virgilio F; Pileggi A; Dhe-Paganon S; Zuccotti GV; Fiorina P
Diabetes; 2018 Oct; 67(10):2038-2053. PubMed ID: 30065030
[TBL] [Abstract][Full Text] [Related]
14. Self-Regulation of Memory CD8 T Cell Metabolism through Extracellular ATP Signaling.
Wanhainen KM; Jameson SC; da Silva HB
Immunometabolism; 2019; 1(1):. PubMed ID: 31428464
[TBL] [Abstract][Full Text] [Related]
15. Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer.
Hofman P; Cherfils-Vicini J; Bazin M; Ilie M; Juhel T; Hébuterne X; Gilson E; Schmid-Alliana A; Boyer O; Adriouch S; Vouret-Craviari V
Cancer Res; 2015 Mar; 75(5):835-45. PubMed ID: 25564520
[TBL] [Abstract][Full Text] [Related]
16. P2RX7 signaling drives the differentiation of Th1 cells through metabolic reprogramming for aerobic glycolysis.
de Salles ÉM; Raeder PL; Angeli CB; Santiago VF; de Souza CN; Ramalho T; Câmara NOS; Palmisano G; Álvarez JM; D'Império Lima MR
Front Immunol; 2023; 14():1140426. PubMed ID: 36993971
[TBL] [Abstract][Full Text] [Related]
17. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.
Hinterleitner R; Gruber T; Pfeifhofer-Obermair C; Lutz-Nicoladoni C; Tzankov A; Schuster M; Penninger JM; Loibner H; Lametschwandtner G; Wolf D; Baier G
PLoS One; 2012; 7(9):e44295. PubMed ID: 22962608
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
19. Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma.
Kodumudi KN; Weber A; Sarnaik AA; Pilon-Thomas S
J Immunol; 2012 Dec; 189(11):5147-54. PubMed ID: 23100512
[TBL] [Abstract][Full Text] [Related]
20. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.
De Marchi E; Orioli E; Pegoraro A; Sangaletti S; Portararo P; Curti A; Colombo MP; Di Virgilio F; Adinolfi E
Oncogene; 2019 May; 38(19):3636-3650. PubMed ID: 30655604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
